Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 25 15 versus DEAPRIL ST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 25 15 versus DEAPRIL ST.
CAPOZIDE 25/15 vs DEAPRIL-ST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of captopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Oral: 1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) once daily initially; titrate to a maximum of 2 tablets twice daily based on blood pressure response.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
None Documented
None Documented
Captopril: ~2 hours (terminal) in normal renal function; increases to 20-60 hours in severe renal impairment. Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Captopril: 95% renally excreted, primarily as unchanged drug and metabolites (disulfide dimers). Hydrochlorothiazide: at least 95% renally excreted as unchanged drug.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
ACE Inhibitor and Diuretic Combination
ACE Inhibitor